GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 50
Summary
- Conditions
- Pancreatic Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Masking Description: Open LabelPrimary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03161379
- Collaborators
- Bristol-Myers Squibb
- Investigators
- Principal Investigator: Daniel Laheru, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Principal Investigator: Arsen Osipov, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Get Well Soon